Recombinant Human IL-28A/IFN-lambda 2 Protein

Newer Version Available: 8417-IL
A New rh IL-28A is Now Available! ~4X fold better activity; Hek293 expressed; No His tag!
Formulations:
Catalog # Availability Size / Price Qty
1587-IL-025
Product Details
Citations (12)
FAQs
Reviews (1)

Recombinant Human IL-28A/IFN-lambda 2 Protein Summary

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED50 for this effect is 10-50 ng/mL.
Source
Mouse myeloma cell line, NS0-derived human IL-28A/IFN-lambda 2 protein
Human IL-28A
Val26-Val200
Accession # NP_742150
DI 6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Val26
Predicted Molecular Mass
20.8 kDa
SDS-PAGE
24 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1587-IL

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

1587-IL/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-28A/IFN-lambda 2

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon. The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.

References
  1. Vilcek, J. (2003) Nature Immunol. 4:8.
  2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
  3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
Long Name
Interleukin 28A
Entrez Gene IDs
282616 (Human)
Alternate Names
interleukin-28A; IFN-lambda 2; IL28A; IL-28A; interferon, lambda 2

Citations for Recombinant Human IL-28A/IFN-lambda 2 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

12 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Interferon lambda receptor 1 (IFNL1R) transcript is highly expressed in rhinovirus bronchiolitis and correlates with disease severity
    Authors: A Pierangeli, M Statzu, R Nenna, L Santinelli, L Petrarca, A Frassanito, M Gentile, G Antonelli, F Midulla, C Scagnolari
    J. Clin. Virol., 2018;102(0):101-109.
    Species: Human
    Sample Types: Whole Cells
    Applications: Stimulation
  2. Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface
    Authors: J Corry, N Arora, CA Good, Y Sadovsky, CB Coyne
    Proc. Natl. Acad. Sci. U.S.A., 2017;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. IFN-?4 potently blocks IFN-? signalling by ISG15 and USP18 in hepatitis C virus infection
    Authors: PS Sung, SH Hong, JH Chung, S Kim, SH Park, HM Kim, SK Yoon, EC Shin
    Sci Rep, 2017;7(1):3821.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling
    Nat. Med., 2016;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation.
    Authors: Persson B, Jaffe A, Fearns R, Danahay H
    PLoS ONE, 2014;9(7):e102368.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth.
    Authors: Ding S, Khoury-Hanold W, Iwasaki A, Robek M
    PLoS Biol, 2014;12(1):e1001758.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-kappaB-mediated MMP-9 expression inducing the MAPK pathway.
    Cell. Signal., 2012;24(9):1734-42.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects.
    Authors: Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M
    Br. J. Cancer, 2011;105(9):1302-12.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages.
    Authors: Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P
    Int. J. Cancer, 2009;125(2):367-73.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.
    Authors: Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K
    Genes Immun., 2009;10(8):702-14.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Biological activity of interleukins-28 and -29: comparison with type I interferons.
    Authors: Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M
    Cytokine, 2005;31(2):109-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human IL-28A/IFN-lambda 2 Protein

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human IL-28A/IFN-lambda 2 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human IL-28A/IFN-lambda 2 Protein
By Anonymous on 06/01/2018
Application: Immunoassay Standard

This recombinant IFN-lambda 2 protein was combined with IFN-lambda 1 (1598-IL) to serve as the calibrator in a pan specific IFN-lambda assay using MAB15981 and BAF1598 as the matched pair antibodies.